How the availability of vast distribution channels propels the growth of the Dermatology Drug market in Middle-East and Africa?
The growth of the Middle East and Africa dermatology drug market is
driven by the escalating occurrence of skin diseases and disorders
across the country. Additionally, rising awareness regarding the
availability of various skincare drugs and the booming demand for
skincare products for curing skin disorders will fuel the growth of the
market. Further, the growing trend of having a better skin appearance
increases the demand for dermatological drugs. The introduction of
customer-centric products is likely to provide the opportunity for the
significant growth of the market. The Middle-East and Africa Dermatology Drug Market is expected to grow at a CAGR of 7% during 2021-26.
Based
on Application, the psoriasis segment is anticipated to grow at a
substantial rate owing to the increasing government initiative to create
psoriasis awareness among people, genetic disposition, and rise in the
ageing population. Moreover, a rise in the practice of unhealthy
lifestyles such as consumption of alcohol, smoking, and high-stress
level is the major factor which is supposed to trigger psoriasis. This
eventually increases the demand for the dermatological drug.
The major leading players in the Middle East and Africa Dermatology Drug Market are Bausch Health Companies Inc., Novartis AG, Pfizer Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co. Inc., Amgen Inc., AbbVie Inc., Eli Lilly and Company, Galderma S.A., GlaxoSmithKline plc, Mylan N.V.
Comments
Post a Comment